We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
GCAF(TMEM251) regulates lysosome biogenesis by activating the mannose-6-phosphate pathway.
- Authors
Zhang, Weichao; Yang, Xi; Li, Yingxiang; Yu, Linchen; Zhang, Bokai; Zhang, Jianchao; Cho, Woo Jung; Venkatarangan, Varsha; Chen, Liang; Burugula, Bala Bharathi; Bui, Sarah; Wang, Yanzhuang; Duan, Cunming; Kitzman, Jacob O.; Li, Ming
- Abstract
The mannose-6-phosphate (M6P) biosynthetic pathway for lysosome biogenesis has been studied for decades and is considered a well-understood topic. However, whether this pathway is regulated remains an open question. In a genome-wide CRISPR/Cas9 knockout screen, we discover TMEM251 as the first regulator of the M6P modification. Deleting TMEM251 causes mistargeting of most lysosomal enzymes due to their loss of M6P modification and accumulation of numerous undigested materials. We further demonstrate that TMEM251 localizes to the Golgi and is required for the cleavage and activity of GNPT, the enzyme that catalyzes M6P modification. In zebrafish, TMEM251 deletion leads to severe developmental defects including heart edema and skeletal dysplasia, which phenocopies Mucolipidosis Type II. Our discovery provides a mechanism for the newly discovered human disease caused by TMEM251 mutations. We name TMEM251 as GNPTAB cleavage and activity factor (GCAF) and its related disease as Mucolipidosis Type V. Lysosomal biogenesis errors often result in diseases including mucolipidosis. Here Zhang and Yang et al. identify TMEM251/GCAF as a mannose-6-phosphate modification regulator that is necessary for correct lysosomal targeting, and classify Mucolipidosis Type V as resulting from GCAF mutations.
- Subjects
LYSOSOMES; SKELETAL dysplasia; HEART abnormalities; CRISPRS; OPEN-ended questions; BRACHYDANIO
- Publication
Nature Communications, 2022, Vol 13, Issue 1, p1
- ISSN
2041-1723
- Publication type
Article
- DOI
10.1038/s41467-022-33025-1